文献速递脊柱关节炎

司库奇尤单抗改善活动性银屑病关节炎症状并抑制影像学进展:随机双盲III期FUTURE 5研究主要结果

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
PubMed 文献 · Ann Rheum Dis · 2018-03-17

FUTURE 5研究纳入996例活动性银屑病关节炎成人患者,随机分配至司库奇尤单抗300mg负荷剂量组、150mg负荷剂量组、150mg无负荷剂量组或安慰剂组。第16周时各司库奇尤单抗组ACR20应答率均显著高于安慰剂组,第24周影像学进展较安慰剂显著抑制,不良事件发生率各组相似。

要点

  • 第16周ACR20应答率:司库奇尤单抗300mg负荷组62.6%、150mg负荷组55.5%、150mg无负荷组59.5%,均高于安慰剂组27.4%(p<0.0001)。
  • 第24周van der Heijde改良总Sharp评分显示的影像学进展在所有司库奇尤单抗组均较安慰剂显著抑制。
  • 第24周不良事件发生率各组相似:300mg负荷组63.1%、150mg负荷组62.7%、150mg无负荷组61.1%、安慰剂组62.0%。

核心结论

  • 皮下注射司库奇尤单抗300mg和150mg(含或不含负荷剂量)在第24周较安慰剂显著改善活动性银屑病关节炎患者的临床体征和症状,并抑制影像学结构进展。

研究设计与样本

  • 随机、双盲、III期FUTURE 5研究,纳入996例活动性银屑病关节炎成人患者,按2:2:2:3随机分配至司库奇尤单抗300mg负荷剂量组、150mg负荷剂量组、150mg无负荷剂量组或安慰剂组。
  • 所有组在基线、第1、2、3周及第4周起每4周给药一次。
  • 主要终点为第16周达到美国风湿病学会20(ACR20)应答的患者比例。

主要发现

  • 第16周ACR20应答率:司库奇尤单抗300mg负荷组62.6%、150mg负荷组55.5%、150mg无负荷组59.5%,均显著高于安慰剂组27.4%(p<0.0001,无应答者填补)。
  • 第24周van der Heijde改良总Sharp评分显示的影像学进展在所有司库奇尤单抗组均较安慰剂显著抑制(300mg负荷组和150mg无负荷组p<0.01,150mg负荷组p<0.05;线性外推)。
  • 第24周不良事件发生率:300mg负荷组63.1%、150mg负荷组62.7%、150mg无负荷组61.1%、安慰剂组62.0%,各组相似。
  • 未报告死亡或新的安全性信号。

关键数值与推荐

  • ACR20应答定义:达到美国风湿病学会20%改善标准。
  • 影像学进展评估采用van der Heijde改良总Sharp评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). METHODS: Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo. All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 weeks from week 4. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at week 16. RESULTS: Significantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p<0.0001 for all; non-responder imputation). Radiographic progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited at week 24 in all secukinumab arms versus placebo (p<0.01 for 300 mg with LD and 150 mg without LD and p<0.05 for 150 mg with LD; linear extrapolation). Adverse event rates at week 24 were similar across treatment arms: 63.1% (300 mg with LD), 62.7% (150 mg with LD), 61.1% (150 mg without LD) and 62.0% (placebo). No deaths or new safety signals were reported. CONCLUSION: S.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clinical signs and symptoms and inhibited radiographic structural progression versus placebo at week 24 in patients with PsA. TRIAL REGISTRATION NUMBER: NCT02404350; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018. PMID: 29550766. doi:10.1136/annrheumdis-2017-212687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。